Skip to main content
. 2023 Mar 17;51(9):4341–4362. doi: 10.1093/nar/gkad172

Figure 2.

Figure 2.

Validation of MEPCE as a synthetic lethal target for BRCA1-mutant tumors. (A) Western blots showing MEPCE expression and representative images of clonogenic growth of indicated BRCA1-WT cells. Cells were fixed after 14–21 days (n = 3). (B) Western blots showing MEPCE expression and representative images of clonogenic growth of indicated BRCA1-mutated cells. Cells were fixed and quantified after 21–28 days (n = 3). (C) Normalized quantification of cells from A and B. (D) Western blot showing MEPCE and BRCA1 expression and representative images of clonogenic growth in indicated cells. Cells were fixed after 14 days of growth (n = 3). (E) In vivo growth curve of indicated xenografts. Tumor volume was measured using external calipers (mean ± SD). Representative images are shown (n = 5 per condition; bar = 1 cm). (F) Quantification of tumor mass post-resection from E (mean ± SEM). (G) Representative images of sectioned tumors from E stained for Ki67 and cleaved CASP3 (bar = 25 μm). Five fields of view were quantified for each tumor (n = 5) (mean ± SEM). Each dot represents a replicate. For A, B and D, 500 cells were seeded in 6 cm dishes. For C, E, F and G, statistical significance was calculated using Student's t-test. For D, statistical significance was calculated using one-way ANOVA (Tukey's multiple comparisons test).